Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Abasaglar ® (insulin glargin)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Nonclinical data for insulin glargine reveal no special hazard for humans based on
conventional studies of safety pharmacology
repeated dose toxicity
genotoxicity
carcinogenic potential, and
toxicity to reproduction.1
Carcinogenesis, Mutagenesis, and Impairment of Fertility With Insulin Glargine
In mice and rats, standard 2-year carcinogenicity studies with another IGlar product were performed at doses up to 0.455 mg/kg, which was for the mouse approximately 5 times and for the rat approximately 10 times the recommended human SC starting dose of 10 units/day (0.008 mg/kg/day), based on mg/m2.2
The findings in female mice were not conclusive due to excessive mortality in all dose groups during the study. Histiocytomas were found at injection sites in male mice (not statistically significant) and male rats (statistically significant) in acid-vehicle containing groups. These tumors were not found in
female animals
saline controls, or
insulin comparator groups using a different vehicle.2
The relevance of these findings to humans is unknown.2
Another IGlar product was not mutagenic in tests for detection of
gene mutations in bacteria and mammalian cells (Ames and HGPRT test), and
chromosomal aberrations (cytogenetics in vitro in V79 cells and in vivo in Chinese hamsters).2
In a combined fertility and prenatal and postnatal study of another IGlar product in male and female rats at SC doses up to 0.36 mg/kg/day, which was approximately 7 times the recommended human SC starting dose of 10 units/day (0.008 mg/kg/day), based on mg/m2, maternal toxicity due to dose-dependent hypoglycemia, including some deaths, was observed. Consequently, a reduction of the rearing rate occurred in the high-dose group only. Similar effects were observed with NPH insulin.2
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2018.
Glossary
Abasaglar = Abasaglar® (insulin glargine) 100 units/mL
HGPRT = hypoxanthine-guanine phosphoribosyltransferase
IGlar = insulin glargine
SC = subcutaneous
Datum fӧr senaste ӧversyn 2019 M02 14